Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2019

01-05-2019 | Dabigatran

Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients

Authors: Bruria Hirsh Raccah, Amihai Rottenstreich, Netanel Zacks, Ilan Matok, Haim D. Danenberg, Arthur Pollak, Yosef Kalish

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2019

Login to get access

Abstract

Direct oral anticoagulants (DOACs) are commonly administered at a level that is lower than that recommended by dose reduction criteria. This raises concern regarding the adequacy of anticoagulation achieved. To evaluate the relationship between inappropriate dosing and DOAC levels. Medical records of atrial fibrillation patients who underwent DOAC level testing during 2013–2017 were reviewed. The primary outcomes were drug levels under and above the expected steady-state range, and in the lowest and highest quartiles. Of 143 patients who underwent DOAC measurements, only 87 (60.8%) received the appropriate dose. Levels under the expected range and in the lowest quartile were found in 11.9% and 15.0% of patients treated with appropriate dosing compared to 21% and 41.5% of patients treated with inappropriately low dose. DOAC levels were above the expected range and in the highest quartile in 23.8% and 32.5% of patients treated with the appropriate dose compared to 7.1% and 9.4% treated with inappropriately low dose. In multivariate analysis, the administration of an appropriate DOAC dose was associated with a lower rate of DOAC in the lowest level (adjusted odds ratio [95% CI] 0.30 (0.12, 0.76), P = 0.011). On the other hand, appropriate dose was associated with drug levels in the highest quartile (odds ratio [95% CI] 3.77 (0.12, 0.76), P = 0.011). Treatment with inappropriately low DOAC dosing compared to appropriate dose is associated with lower DOAC levels. However, among those treated with appropriate dosing, a higher proportion had high DOAC levels above the expected range.
Appendix
Available only for authorised users
Literature
3.
go back to reference Kirchhof P, Uk C, Uk DK et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the Europ. Eur Heart J 37(38):7–90. https://doi.org/10.1093/eurheartj/ehw210 CrossRef Kirchhof P, Uk C, Uk DK et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the Europ. Eur Heart J 37(38):7–90. https://​doi.​org/​10.​1093/​eurheartj/​ehw210 CrossRef
4.
go back to reference Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRef Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992CrossRef
6.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRef Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRef
10.
go back to reference Howard M, Lipshutz A, Roess B et al (2017) Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. J Thromb Thrombolysis 43(2):149–156CrossRefPubMed Howard M, Lipshutz A, Roess B et al (2017) Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants. J Thromb Thrombolysis 43(2):149–156CrossRefPubMed
13.
go back to reference Ryn J, Van Stangier J, Haertter S, Liesenfeld K, Wienen W, Feuring M (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6):1116–1127. https://doi.org/10.1160/TH09-11-0758 CrossRef Ryn J, Van Stangier J, Haertter S, Liesenfeld K, Wienen W, Feuring M (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103(6):1116–1127. https://​doi.​org/​10.​1160/​TH09-11-0758 CrossRef
Metadata
Title
Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients
Authors
Bruria Hirsh Raccah
Amihai Rottenstreich
Netanel Zacks
Ilan Matok
Haim D. Danenberg
Arthur Pollak
Yosef Kalish
Publication date
01-05-2019
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2019
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-019-01815-y

Other articles of this Issue 4/2019

Journal of Thrombosis and Thrombolysis 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.